phrykt

Lantern Pharma Inc. (LTRN): who owns it and who trades it

As of Nov 16, 2026, LTRN insiders reported 1 purchase worth $100K in the last 12 months. The largest buyer was Lee Troy Schalop (Director), with $100K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Lantern Pharma

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns LTRN

39 funds and institutions reported LTRN shares worth $12M at the end of Q2 2026, about 26% of the company. The largest holder is Empery Asset Management, LP with 7.5%.

Funds and institutions (13F) 26%Everyone else 74%

10 largest owners, by share of the company

Empery Asset Management, LP7.5%
CM Management, LLC4.4%
Vanguard Capital Management LLC3.8%
Renaissance Technologies LLC2.6%
BIOS Capital Management, LP2.2%
Geode Capital Management, LLC0.9%
Vanguard Fiduciary Trust Co0.4%
Citadel Advisors LLC0.4%
Westside Investment Management, Inc.0.4%
Quadrature Capital Ltd0.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Empery Asset Management, LP842,6697.49%$3.5M–
CM Management, LLC500,0004.44%$2.1M–
Vanguard Capital Management LLC425,1183.78%$1.8M–
Renaissance Technologies LLC291,0392.59%$1.2M–
BIOS Capital Management, LP249,3972.22%$1M–
Geode Capital Management, LLC102,8190.91%$429K–
Vanguard Fiduciary Trust Co49,9500.44%$208K–
Citadel Advisors LLC47,8950.43%$200K–
Westside Investment Management, Inc.47,8500.43%$200K–
Quadrature Capital Ltd39,5930.35%$165K–
NewEdge Advisors, LLC27,0490.24%$113K–
Horizon Kinetics Asset Management LLC25,1640.22%$105K–
DAVENPORT & Co LLC23,8140.21%$99.3K–
State Street Corp23,6520.21%$98.6K–
BlackRock, Inc.22,3500.20%$93.2K–
Bank of New York Mellon Corp21,3010.19%$88.8K–
Northern Trust Corp17,4850.16%$72.9K–
XTX Topco Ltd17,4150.15%$72.6K–
Dimensional Fund Advisors LP16,7250.15%$69.7K–
UBS Group AG16,6320.15%$69.4K–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, LTRN insiders reported $100K of open-market purchases and $0 of sales.

Purchases, 12 months
$100K
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
May 12, 2026
Filed May 14, 2026

Purchases and sales by month

$100K$100KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
May 12, 2026Lee Troy SchalopDirectorPurchase48,544$2.06$100KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Lee Troy SchalopDirector$100K–May 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

LTRN short interest

Moderate short interest. 7.2% of LTRN shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went down 51%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 924,479 LTRN shares were sold short, 7.2% of the shares outstanding, up 137.9% from the report before. At the average daily volume of 345,314 shares, buying them all back would take about 2.7 trading days (days to cover).

Shares short, % of all shares

7.23%May 15Oct 3019.0%

Days to cover

2.7May 15Oct 3011.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026924,4797.23%+138%345,3142.7
Oct 15, 2026388,6553.04%-20%259,3301.5
Sep 30, 2026485,7503.80%-13%369,5381.3
Sep 15, 2026557,9814.36%-1%167,3763.3
Aug 31, 2026564,6324.42%-19%135,7184.2
Aug 14, 2026693,0345.42%-18%85,7848.1
Jul 31, 2026846,3727.52%-10%83,91710.1
Jul 15, 2026945,2168.40%+2%184,3845.1
Jun 30, 2026929,0518.25%-32%179,6135.2
Jun 15, 20261.37M12.16%-7%230,4155.9
May 29, 20261.48M13.13%-22%256,8965.8
May 15, 20261.90M16.90%-6%355,7315.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Lantern Pharma company events

Lantern Pharma filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (listing). The latest was on Oct 1, 2026.

  1. Oct 1, 2026ListingLantern Pharma Inc. received notice from The Nasdaq Stock Market LLC that the Company is not in compliance with Nasdaq’s Listing Rule 5550(b)(2), as the market value of listed securities for the Company’s common stock had been below the minimum MVLS Requirement of $35 million for the last 30… Filing
  2. Sep 30, 2026AgreementLantern Pharma Inc. entered into a securities purchase agreement with an institutional investor, pursuant to which the Company agreed to issue and sell to such investor in a registered direct offering (i) 1,469,725 shares of common stock, par value $0.0001 per share, of the Company, at an offering… Filing
  3. Sep 24, 2026AnnouncementShared information with investors. Filing
  4. Sep 23, 2026AnnouncementShared information with investors. Filing
  5. Aug 14, 2026ResultsReleased financial results. Filing
  6. Aug 3, 2026AnnouncementShared information with investors. Filing
  7. Jun 2, 2026AnnouncementShared information with investors. Filing
  8. May 15, 2026ResultsReleased financial results. Filing
  9. May 14, 2026AgreementLantern Pharma Inc. entered into a securities purchase agreement with institutional investors, pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering (i) 1,454,175 shares of common stock, par value $0.0001 per share, of the Company, at an offering… Filing
  10. Apr 10, 2026AnnouncementShared information with investors. Filing
  11. Mar 30, 2026ResultsReleased financial results. Filing
  12. Jan 23, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Lantern Pharma financials

Famous investors that hold LTRN

1 of the 50 well-known investors we track reported holding LTRN in their latest 13F filing. The largest position is Jim Simons's, worth $372K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026368,407$372K0.0%+27%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named LTRN in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Armistice Capital, LLC13G10.0%
Nov 16, 2026Armistice Capital, LLC13G10.0%
Oct 13, 2026Empery Asset Management, LP13G/A5.0%
Oct 13, 2026Empery Asset Management, LP13G/A5.0%

Questions about Lantern Pharma Inc. (LTRN) stock

Who owns the most LTRN stock?

The largest reported owner of Lantern Pharma Inc. (LTRN) is Empery Asset Management, LP, with 7.5% of the company. In total, 39 funds and institutions reported holding LTRN at the end of Q2 2026, together about 26% of the shares. See the largest owners.

Are LTRN insiders buying or selling?

In the last 12 months, LTRN insiders reported 1 open-market purchase worth $100K and no sales. The latest trade was on May 12, 2026. See every trade.

What is the short interest in LTRN?

As of Oct 30, 2026, 924,479 LTRN shares were sold short, 7.2% of the shares outstanding, up 137.9% from the report before. At the average daily volume of 345,314 shares, buying them all back would take about 2.7 trading days (days to cover). See the history.

Which famous investors hold LTRN?

1 of the 50 well-known investors we track reported LTRN in their latest 13F filing, including Jim Simons. The largest position is worth $372K. See all holders.

Executive pay

Lantern Pharma's chief executive was paid a total of $764K for the year ended Dec 31, 2025, down 30% from $1.1M the year before. In the last 12 months, Lantern Pharma's executives and directors bought $100K of stock on the open market and sold none.

Chief executive, total pay$764KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$779KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$415KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.